Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02305602
Other study ID # CV-201
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2015
Est. completion date June 2019

Study information

Verified date October 2019
Source Ventrix, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase I, open label, study will investigate the effects of VentriGel injection in patients who have experienced a first, large ST elevation myocardial infarction (STEMI) treated by PCI within the past 3 years and have evidence of left ventricular remodeling.


Description:

Evaluate the safety and feasibility of VentriGel delivered trans-endocardially to subjects with left ventricular ejection fraction (LVEF) 25 to 45% secondary to MI. Secondary endpoints will look at efficacy variables of ESV, EDV, EF, scar mass.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date June 2019
Est. primary completion date September 5, 2018
Accepts healthy volunteers No
Gender All
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria:

1. The subject is 30-75 years of age

2. The subject must be able to provide informed consent

3. At least 60 days and no more than 3 years will have passed since the first ST elevation myocardial infarction (Index STEMI) at time of VentriGel administration

4. The Index STEMI must meet the following criteria:

1. First time diagnosis of STEMI AND;

2. Meet the STEMI criteria of the American College of Cardiology (ACC)/American Heart Association (AHA) (e.g. ST elevation in at least 2 contiguous leads >0.2 mV in V1, V2 or V3 and/or >0.1mV in at least two other leads), or new left bundle branch block (LBBB)

5. Evidence of left ventricular remodeling secondary to the myocardial infarction using 2-D echocardiography or cMR;

1. the LVEF must be = 25% and = 45% AND;

2. The left ventricular wall thickness is = 8 mm in target area.

6. Successful percutaneous coronary intervention (PCI) restoring TIMI II of higher flow to infarcted area

7. Negative pregnancy test [serum human chorionic gonadotropin (ßhCG)] in women of childbearing potential within 24 hours prior to dosing) or if less than 2 years postmenopausal agree to use of adequate contraception during the study.

8. Must be ambulatory, willing and able to comply with protocol, including follow-up visits

9. Subject must be receiving best medical treatment for their post-MI clinical presentation according to the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines

10. For those subjects indicated for heart failure medical therapy, subjects must be on stable therapy including beta-blockers and angiotensin converting enzyme inhibitors, if tolerated, for at least 45 days prior to therapy delivery

Exclusion Criteria:

1. Contraindications to cardiac MR

2. NYHA Functional Classification 4 heart failure within the prior 6 months.

3. Significant coronary artery stenosis that may require percutaneous or surgical revascularization within six months of enrollment, as determined by the principal investigator

4. Left ventricular thrombus, left ventricular aneurysm, subjects with post-infarction pericarditis, or subjects with wall motion abnormalities outside the region of the infarct related artery

5. Frequent, recurrent, sustained (>30 seconds) ventricular tachycardia in 30 days prior to VentriGel administration

6. ECG or 24 hour Holter Monitor with any of the following findings:

- Bifascicular block (left bundle branch block or right bundle branch block plus left hemi-block)

- Higher grade AV block (i.e. 3rd degree)

- Ventricular tachycardia (>= 5 seconds of VT OR any symptomatic VT)

7. Atrial fibrillation with heart rate greater than 110 bpm.

8. Severe valvular disease (e.g. aortic stenosis of moderate or worse severity, valvular insufficiency requiring surgical repair) or history of heart valve replacement.

9. Known allergy to porcine proteins or prior implantation of a porcine derived medical product including cardiac valves or other ECM products.

10. Etiology of heart failure due to any cause (e.g. hypertrophic cardiomyopathies, restrictive cardiomyopathies, constrictive pericardial disease, amyloidosis, active myocarditis) other than the index MI.

11. Severe peripheral vascular disease that impairs femoral arterial access.

12. Less than 3 years, cancer free, since end of treatment for cancer (with exception of basal cell carcinoma)

13. Alcohol or drug dependency within six months prior to enrollment

14. Cerebrovascular event within the 90 days prior or major surgical procedure or major trauma within the 14 days prior to enrollment

15. Participation, defined as receiving test article, in an experimental clinical study within 30 days prior to administration of VentriGel (i.e. screen failure from other study does not exclude subject)

16. Uncontrolled hypertension defined as systolic blood pressure (SBP) > 180 mmHg and/or or diastolic blood pressure (DBP) >110 mmHg

17. Abnormal laboratory values as defined below performed at screening:

- Aspartate aminotransferase [AST]/ alanine aminotransferase [ALT] = 3 times upper limit of normal (ULN)

- Serum creatinine = 2.0 mg/dL

- Platelet count < 50,000/mm3

- Hemoglobin < 9.0 g/dL

- HbA1c > 9.0%

- PT or aPTT with clinically significant elevations relative to local laboratory norms

18. Any other cardiac or non-cardiac conditions or illness which, in the opinion of the principal investigator, may place subjects at undue risk or compromise the objectives of the study.

19. Institutional interpretation of cMR EF data outside the = 25% and = 45% limits

Study Design


Intervention

Biological:
VentriGel
VentriGel will be injected via MyoStar catheter after NOGA mapping

Locations

Country Name City State
United States Rush University Medical Center Chicago Illinois
United States University of Florida Gainesville Florida
United States Mercy Gilbert Medical Center Gilbert Arizona
United States Cedars-Sinai Medical Center Los Angeles California
United States Minneapolis Heart Institute Minneapolis Minnesota
United States University of Utah Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Ventrix, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of serious adverse events that occur within 6 months of injection 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy